Skip to main content
Premium Trial:

Request an Annual Quote

Nuvelo s Revenues Plunge, Losses Rise in Q1

NEW YORK, May 7 (GenomeWeb News) - Nuvelo yesterday reported increased losses and a drop in revenues for the first quarter of 2004.

 

Nuvelo's revenues plunged to $0.6 million, compared with $1.3 million in the first quarter of 2003. Net losses rose to $17.7 million, or $.65 per share, from year-ago losses of $13.6 million, or $.82 per share.

 

R&D expenses rose to $16.3 million in the quarter, compared with $10.8 million in the first quarter of 2003.

 

As of March 31, 2004, Nuvelo had $94 million in cash, cash equivalents, and short-term investments.

 

The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.